What is the definition of Exfoliative Dermatitis?

Exfoliative dermatitis, also known as erythroderma, is a severe, widespread inflammation of the skin often caused by a pre-existing skin condition, cancer, or a reaction to certain medications, such as chemotherapy.

What are the symptoms for Exfoliative Dermatitis?

Symptoms of exfoliative dermatitis include extreme redness of the skin with patches that spread, scale, peel, flake, itch, and slough, crusting lesions, thickened skin, malaise, fever, loss of temperature regulation, skin infections, swollen lymph nodes, increased heart rate, dehydration from loss of fluids, and protein deficiency from protein loss through the skin. Exfoliative dermatitis can spread to 80-90% of the body (generalized) and be life-threatening.

What are the current treatments for Exfoliative Dermatitis?

Treatment for exfoliative dermatitis includes determining whether it may have been caused by any medications, such as penicillin or barbiturates, and discontinuing them; evaluation and treatment for any underlying atopic dermatitis skin disease; heated blankets; cool baths; petroleum jelly applied to skin with bandaging; rehydration; and preventing infection. Individuals with severe, generalized exfoliative dermatitis my need to be treated in the hospital with intravenous (IV) fluids, nutritional supplements, ultraviolet light, systemic corticosteroids, and antibiotics.
  • Journal: Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
  • Published —
Mycosis fungoides and Sézary syndrome.
  • Journal: Zhonghua shao shang za zhi = Zhonghua shaoshang zazhi = Chinese journal of burns
  • Published —
Analysis of the clinical features and prognostic influencing factors of toxic epidermal necrolysis.
Clinical Trial
  • Status: Recruiting
  • Phase: Phase 2
  • Intervention Type: Biological
  • Participants: 15
  • Start Date: October 3, 2019
An Open Label Pilot Trial of Guselkumab in the Treatment of Adults With Pityriasis Rubra Pilaris (PRP)
Clinical Trial
  • Status: Enrolling by invitation
  • Phase: Phase 1
  • Intervention Type: Drug
  • Participants: 12
  • Start Date: April 1, 2018
Cosentyx (Secukinumab) for the Treatment of Adult Onset Pityriasis Rubra Pilaris: A Single Arm, Open-label Exploratory Trial